Detection rates of high-grade prostate cancer during subsequent screening visits. Results of the European Randomized Screening Study for Prostate Cancer.
作者:
van der Kwast(Theodorus H),Ciatto(Stefano),Martikainen(Paula M),Hoedemaeker(Robert),Laurila(Marita),Pihl(Carl-Gustaph),Hugosson(Jonas),Neetens(Ingrid),Nelen(Vera),Di Lollo(Simonetta),Roobol(Monique J),Määtänen(Liisa),Santonja(Carlos),Moss(Sue),Schröder(Fritz H)
状态:
发布时间2006-03-06
, 更新时间 2016-11-22
期刊:
Int J Cancer
摘要:
Screening for prostate cancer using prostate-specific antigen (PSA) tests has led to a stage and grade shift as compared to the pre-PSA era. Effectiveness of screening for prostate cancer should be manifested by a reduction in detection rate of aggressive cancers during subsequent screening. In 6 centers of the European Randomized Screening study for Prostate Cancer, a total of 58,710 men were tested for prostate cancer. Screening centers differed with regard to age-range, screening interval and biopsy indications. During the 2nd visit, the proportion of Gleason score 6 cancers increased from 62.5 to 75%, mainly at the expense of Gleason score 7 cancers. High-grade (Gleason score 8-10) cancer detection rates varied per screening center during the 1st visit from 5.1 to 41.1, and during the 2nd visit from 6.4 to 29.3/10,000 men. The overall detection rate of high-grade cancers showed a reduction during the 2nd visit from 26 to 12/10,000 men, an effect mainly attributable to the screening center with the highest cancer detection rate (i.e. 507/10,000 men). Variations in detection rates among screening centers related among others to biopsy compliance and age range.